Posted in | News | Dendrimers | Nanobusiness

Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays

Genisphere has announced the adaption of its breakthrough 3DNA dendrimer signal amplification technology for use in lateral flow (LF) point-of-care (POC) assays, delivering enhanced sensitivity and facilitating a variety of new POC tests.

LF assays are a special and promising suite of POC tests intended to perform rapid diagnosis within clinically actionable timelines. Genisphere’s 3DNA signal amplifiers help in bringing new LF assays to the marketplace, which is otherwise not possible because of very low sensitivity, and provide a competitive edge to test-makers in the POC testing market, which is crowded with products limited by quantitative accuracy and sensitivity.

These advancements build on earlier signal amplification capabilities demonstrated in systems such as DNA and protein arrays, ELISA, and Luminex assays. Genisphere will exhibit its 3DNA dendrimer nanotechnology at the 012 American Association for Clinical Chemistry Annual Meeting and Clinical Lab Expo, which will be conducted in Los Angeles from July 15 to 19, 2012.

Genisphere’s proprietary 3DNA dendrimer technology has demonstrated a 64-fold increase in sensitivity when compared to typical non-dendrimer assays. This superior sensitivity enables the technology to decrease false negatives and considerably improve the accuracy of outcome readings. This technology will allow the POC market to provide high-sensitive rapid testing for a myriad of conditions, including coronary biomarkers, bacterial sepsis, infectious diseases, environmental and water testing, and food microbiological testing, which are not possible with existing systems.

Genisphere’s Vice President and Chief Operating Officer, Jim Kadushin stated that the company has achieved its objective of delivering a powerful and user-friendly reagent that can be used by manufacturers in their bioassay platforms with minimal adaptation and without end user modifications.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2019, February 12). Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays. AZoNano. Retrieved on November 24, 2024 from https://www.azonano.com/news.aspx?newsID=25271.

  • MLA

    Thomas, G.P.. "Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays". AZoNano. 24 November 2024. <https://www.azonano.com/news.aspx?newsID=25271>.

  • Chicago

    Thomas, G.P.. "Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays". AZoNano. https://www.azonano.com/news.aspx?newsID=25271. (accessed November 24, 2024).

  • Harvard

    Thomas, G.P.. 2019. Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays. AZoNano, viewed 24 November 2024, https://www.azonano.com/news.aspx?newsID=25271.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.